High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors

SIMPLE SUMMARY: Multitargeted tyrosine kinase inhibitors (TKIs) provide clinical benefit in patients with cancer when daily dosed to continuously inhibit their designated targets. Alternative dosing strategies pursuing higher tumor drug concentrations may improve their benefit by inhibiting relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerritse, Sophie L., Labots, Mariette, Heine, Rob Ter, Dekker, Henk, Poel, Dennis, Tauriello, Daniele V. F., Nagtegaal, Iris D., Van Den Hombergh, Erik, Van Erp, Nielka, Verheul, Henk M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775433/
https://www.ncbi.nlm.nih.gov/pubmed/36551546
http://dx.doi.org/10.3390/cancers14246061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775433/
https://www.ncbi.nlm.nih.gov/pubmed/36551546
http://dx.doi.org/10.3390/cancers14246061

Ejemplares similares